Singapore, April 15 -- Cellino, a biotechnology company pioneering autonomous biomanufacturing for personalised regenerative medicine, has announced its expansion into the Asia-Pacific region through a strategic collaboration with Karis Bio, a leading South Korean cell therapy biotech. The partnership aims to industrialize the world's first clinical-stage autologous induced pluripotent stem cell (iPSC)-derived cell therapy for peripheral artery disease (PAD) and coronary artery disease (CAD).

The collaboration is set to accelerate the development of Karis Bio's innovative autologous iPSC-derived endothelial cell (iPSC-EC) therapy designed to generate new blood vessels in ischemic organs. Karis Bio's first-in-human clinical study in South...